BioSniper
Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzol

October 1, 2028
Company
Celldex Therapeutics, Inc. (CLDX)
Drug
barzolvolimab
Indication
Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria

Other upcoming events for CLDX

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
Apr 1, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
Apr 1, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chron
Sep 1, 2028

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
CLDX OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle